Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.34 USD | -3.35% | -5.23% | -29.48% |
Financials (USD)
Sales 2024 * | 223M | Sales 2025 * | 321M | Capitalization | 499M |
---|---|---|---|---|---|
Net income 2024 * | -284M | Net income 2025 * | -148M | EV / Sales 2024 * | 2.74 x |
Net Debt 2024 * | 112M | Net Debt 2025 * | 118M | EV / Sales 2025 * | 1.93 x |
P/E ratio 2024 * |
-1.88
x | P/E ratio 2025 * |
-3.89
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.25% |
Latest transcript on Travere Therapeutics, Inc.
1 day | -3.35% | ||
1 week | -6.76% | ||
Current month | +14.65% | ||
1 month | +8.38% | ||
3 months | -19.34% | ||
6 months | +10.84% | ||
Current year | -29.48% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 19-01-03 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 14-07-31 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 22-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 15-03-30 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 14-10-07 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 20-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - | |
0.06% | 1,487 M€ | +8.16% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 6.34 | -3.35% | 1,147,369 |
24-05-22 | 6.56 | -0.76% | 811,497 |
24-05-21 | 6.61 | +7.13% | 1,389,666 |
24-05-20 | 6.17 | +1.82% | 909,628 |
24-05-17 | 6.06 | -9.42% | 1,321,572 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.48% | 499M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- TVTX Stock